Therapy and clinical trials: Aggressive statin therapy versus combined and emerging approaches

Current Opinion in Lipidology

Volumn 22, Issue 4, 2011, Pages 324-325

  Catapano, Alberico L ^a,c   Norata, Giuseppe D ^a,b   Pirillo, Angela ^b,c  

^a UNIVERSITY OF MILAN   (Italy)

^b Bassini Hospital   (Italy)

^c IRCCS MULTIMEDICA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; EZETIMIBE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; ROSUVASTATIN; SIMVASTATIN; STATIN;

ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; CONFIDENCE INTERVAL; DRUG EFFICACY; DRUG SAFETY; HAZARD RATIO; INCIDENCE; ISCHEMIC HEART DISEASE; NOTE; PRIORITY JOURNAL;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; CLINICAL TRIALS AS TOPIC; DYSLIPIDEMIAS; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PYRIMIDINES; PYRROLES; SIMVASTATIN; SULFONAMIDES;

EID: 79960643892     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e328348a513     Document Type: Note

References (8)

1. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010; 376:1670-1681.
2. Armitage J, Bowman L, Wallendszus K, et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 2010; 376:1658-1669.
3. Pedersen TR, Cater NB, Faergeman O, et al. Comparison of atorvastatin 80. mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial). Am J Cardiol 2010; 106:354-359.
4. Villines TC, Stanek EJ, Devine PJ, et al. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol 2010; 55:2721-2726.
5. Crouse JR 3rd, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR trial. JAMA 2007; 297:1344-1353. (Pubitemid 46513235)
6. Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011; 364:127-135.
7. Nicholls SJ, Gordon A, Johansson J, et al. Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease: a randomized controlled trial. J Am Coll Cardiol 2011; 57:1111-1119.
8. Bailey D, Jahagirdar R, Gordon A, et al. RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. J Am Coll Cardiol 2010; 55:2580-2589.